Q: What is Novo Nordisk’s current positioning in the Mexican market, and what are the primary factors driving the company’s recent growth in the country?
A: Novo Nordisk has achieved outstanding performance in Mexico over the past three and a half years. Our local affiliate has successfully tripled in size, driven not only by our commitment to introducing cutting-edge medical innovation but also by substantially increasing our investments in local clinical trials. Our team has grown to over 400 employees, reflecting our strong upward trajectory within the Mexican healthcare market.
A significant portion of this growth is anchored in our strategic focus on obesity, a therapeutic area that has evolved dramatically over the last two years. By pairing innovation with robust medical education, we are actively reshaping the narrative around obesity, establishing it clearly as a chronic, multi-factorial disease. Our goal is to eradicate the social stigma surrounding obesity. As society gains a deeper clinical understanding of the condition, there is a growing recognition that treating obesity early is vital to preventing a secondary cascade of related chronic illnesses.
Q: How do diabetes and obesity impact corporate productivity, labor competitiveness, and operational costs like absenteeism?
A: The statistics are staggering: three out of every four adults in Mexico live with overweight or obesity. This directly impairs corporate competitiveness through heightened absenteeism and early retirements. Furthermore, there are over 200 medical comorbidities directly linked to overweight conditions that are often left out of public discourse.
Diabetes is one of the most prominent and costly comorbidities. In Mexico, the prevalence of diabetes stands at 18.3%, while pre-diabetes affects 22.1% of the population. When healthcare systems and employers effectively treat obesity, they create a preventative shield against these 200 associated conditions, including diabetes, which currently represents the highest financial burden for the Mexican Social Security Institute (IMSS). To address this, Novo Nordisk actively partners with major corporations to analyze corporate populations, evaluate health risks, and implement preventative health programs to mitigate medical absenteeism.
We have established strong health initiatives with enterprises in Monterrey and Mexico City. We firmly believe that change begins internally; at Novo Nordisk, we provide our employees with dedicated in-house physicians, nutritionists, and regular biometric tracking to foster a culture of wellness from within.
Q: In terms of public health expenditure, what are the hidden financial burdens of chronic illnesses on institutions like IMSS, and how can the system transition toward a sustainable long-term preventative model?
A: IMSS allocates about MX$38.8 billion (US$2.23 billion) annually solely to manage diabetes mellitus. Transitioning to a sustainable model requires treating the root causes — overweight and obesity — which dynamically reduces the downstream incidence of these expensive chronic illnesses.
However, the core challenge lies in shifting the institutional mindset. The healthcare sector frequently prioritizes short-term expenditure metrics because budgets are allocated on an annual or biannual basis. This structural setup discourages long-term investments in prevention. To build a truly resilient and sustainable healthcare framework, we must evaluate longitudinal indicators, such as a reduction in emergency room visits, decreased hospitalization rates, and fewer secondary complications. Preventing long-term complications is the only viable mechanism to curb future public health expenditures and guarantee aggregate system sustainability.
Q: The introduction of GLP-1 receptor agonists has revolutionized obesity care globally. How are these medical innovations reshaping both the clinical treatment protocols and the broader public perception of obesity?
A: The introduction of GLP-1 receptor agonists represents a fundamental paradigm shift in modern medicine. These innovations do more than provide a clinical pathway for managing a chronic disease; they are fundamentally redefining how the global medical community views obesity. We have actively marketed these therapies in Mexico for the past year and a half, though we initially observed their transformative impact on disease progression through our existing diabetes patient portfolios.
Crucially, these therapies demonstrate that effective obesity care extends far beyond weight loss metrics. We are observing profound systemic health benefits, including improvements in orthopedic conditions, reductions in body mass index, and a lower incidence of weight-related cancers. Statistically, living with obesity increases an individual’s risk of related health complications by 27%, while also severely impacting fertility and exacerbating menopausal symptoms. Most notably, GLP-1 therapies have shown a significant capacity to reduce cardiovascular risks, which remain a leading cause of mortality across Mexico and Latin America. These treatments are profoundly life-changing because they shift the medical conversation away from cosmetic weight loss and focus entirely on long-term systemic health preservation.
Q: How is Novo Nordisk supporting Mexico as it transforms the management of chronic diseases?
A: Mexico serves as a premier model for how to build an equitable healthcare infrastructure for chronic diseases. Over the past two years, Novo Nordisk has worked closely with the Ministry of Health and IMSS to incorporate modern obesity care into public frameworks. Thanks to this collaborative effort, the public health sector has officially approved dedicated therapeutic codes to treat overweight and obesity. By integrating these protocols into the public paradigm, Mexico is ensuring equitable access to care. Patients are no longer entirely dependent on the private sector to receive advanced therapies. This successfully bridges the gap between private options and public access, establishing a balanced, equitable, and highly integrated infrastructure that addresses the nationwide chronic disease crisis.
While the Mexican market historically features high out-of-pocket healthcare expenses, our strategic focus remains balanced. Until recently, our public sector access codes primarily covered diabetes treatments. However, the recent inclusion of specific public sector codes for overweight and obesity management marks a major operational milestone. Moving forward, we will continue working with the Ministry of Health to ensure this structural balance remains robust, allowing us to serve patients efficiently across both public health institutions and private commercial channels.
Q: What is the current scale of Novo Nordisk’s clinical trial infrastructure in Mexico, and what are your projections for future investment?
A: Novo Nordisk is deeply committed to Mexico, and we are on track to triple our investments in local clinical trials by 2030. We now manage 27 active clinical studies nationwide, with an additional 11 protocols under regulatory review with COFEPRIS. We anticipate securing these upcoming approvals within the next three to six months.
This significant expansion has required a proportional scale-up of our specialized local workforce to successfully manage these protocols. Furthermore, we have finalized a landmark strategic alliance with the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ). Through this partnership, we are successfully deploying international, ethically synchronized clinical research protocols directly within the Mexican public health system, ensuring that advanced clinical research benefits a diverse and representative patient population.
Q: Novo Nordisk previously established a Global Business Services (GBS) hub in Mexico to support North American and Latin American operations. What role does this center play in your broader corporate structure?
A: Our Global Business Services hub in Mexico has scaled rapidly and now employs over 100 highly specialized professionals. This center plays an essential operational role, providing advanced support for our expanding clinical trial operations across both the United States and Latin America. The successful growth of this hub has elevated our local affiliate’s standing within the corporate structure. Novo Nordisk Mexico is now officially recognized as one of the top ten most critical affiliates globally for the parent company. This ranking highlights our exceptional commercial growth, our expanding employment footprint over the last three years, and our capacity to execute complex operational mandates. Mexico represents an extraordinary, high-priority investment landscape where we will continue to anchor long-term corporate resources.
Q: What have been the core drivers behind Novo Nordisk commercial success and institutional leadership in Mexico?
A: Transitioning to a market of Mexico’s scale has been an extraordinary professional journey, made possible by the exceptional talent within our local organization. Our commercial success and institutional leadership stem from a single variable: maintaining an absolute, unwavering focus on the patient. When an organization aligns its operational compass entirely with patient outcomes, the path to navigating complex public and private environments becomes very clear.
Our overarching goal is to ensure that Mexican patients receive timely access to the absolute highest tier of medical innovation. Because our corporate objectives directly mirror the public sector’s goal of fostering a healthier population, we have been able to build strong, highly productive institutional relationships. We demonstrate our long-term commitment to the country through sustained clinical trial investments and continuous medical education. In the first quarter of this year, Mexico successfully secured its position among Novo Nordisk’s top 10 global affiliates, a powerful testament to our team’s execution and the bright future ahead for healthcare innovation in this market.